pharma · Chronic obstructive pulmonary disease (COPD) · Partial Epilepsy in Children and Adolescents
Bial Portela &
Bial Portela & Companhia S.A.
Bial Portela & is a pharma organization headquartered in EU. Primary therapeutic focus areas include Chronic obstructive pulmonary disease (COPD), Partial Epilepsy in Children and Adolescents, Intermediate and high-risk
EU HQ
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Programs
- 7
- Drugs
- 7
- Patents
- 3
Eslicarbazepine acetate (BIA 2-093)
Phase 3 · small molecule · Partial Epilepsy in Children and Adolescents
Eslicarbazepine acetate (BIA 2-093) for Partial Epilepsy in Children and Adolescents is a Phase 3 program (small_molecule) at Bial Portela & Companhia S.A. with 1 ClinicalTrials.gov record(s).
Internal code BIA-2093-305
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Bial Portela & Companhia S.A.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Partial Epilepsy in Children and Adolescents
- Status
- completed
- Trials
- 1